Abstract
The renin-angiotensin-aldosterone system (RAAS) is critical in regulating systemic blood pressure, water and electrolyte balance, and pituitary gland hormones. These physiologies appear to be primarily mediated by the angiotensin II/AT1 receptor subtype system. Overstimulation of this system can predispose cardiovascular disease (CVD) characterized by excessive vasoconstriction, fibrosis, and cardiac remodeling. If untreated, the patient typically displays a continuum of pathophysiologic conditions progressing from atherosclerosis to left ventricle hypertrophy (LVH), coronary thrombosis, myocardial infarcts, with heart failure as an endpoint. Intervention with antihypertensive therapy is necessary to inhibit this progression. RAAS blocking drugs appear to be the most effective approach. Diastolic heart failure patients benefit from treatment with angiotensin converting enzyme (ACE) inhibitors and angiotensin AT1 receptor blockers (ARBs). Elderly CVD patients evidence age-related changes in body composition that alter the distribution and half-life of medications, thus presenting special challenges to treatment. The presence of comorbidities such as diabetes, renal dysfunction, liver insufficiency further complicates any therapeutic strategy. In addition, noncompliance because of cognitive impairment, depression, confusion due to the complexity of dose regimens, and lack of an appropriate social support system can disrupt positive outcome. The present review discusses the roles of an overactive RAAS and sympathetic nervous system as primary contributors to CVD. In addition, treatment strategies are discussed, focusing on middle aged and elderly hypertensive and heart failure patients.
Similar content being viewed by others
References
Dzau V, Braunwald E (1991) Resolved and unresolved issues in the prevention and treatment of coronary artery disease: a workshop consensus statement. Am Heart J 121:1244–1263
Dzau V (2005) The cardiovascular continuum and renin-angiotensin-aldosterone system blockade. J Hypertens 23:S9–S17
Dzau VJ, Antman EM, Black HR, Hayes DL, Manson JE, Plutzky J, Popma JJ, Stevenson W (2006) The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes. Part I: pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease). Circulation 114:2850–2870
Baker KM, Booz GW, Dostal DE (1992) Cardiac actions of angiotensin II: role of an intracardiac renin-angiotensin system. Annu Rev Physiol 54:227–241
Mehta PK, Griendling KK (2006) Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol 292:C82–C97
Schieffer B, Schieffer E, Hilfiker-Kleiner D, Hilfiker A, Kovanen PT, Kaartinen M et al (2000) Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability. Circulation 101:1372–1378
Adams KF (2004) Pathophysiologic role of the renin-angiotensin-aldosterone and sympathetic nervous systems in heart failure. Am J Health Syst Pharm 61(Suppl 2):S4–S13
Unger T (2002) The role of the renin-angiotensin system in the development of cardiovascular disease. Am J Cardiol 89:3A–10A
Schena M, Mulatero P, Schiavone D, Mengozzi G, Tesio L, Chiandussi L, Veglio F (1999) Vasoactive hormones induce nitric oxide synthase mRNA expression and nitric oxide production in human endothelial cells and monocytes. Am J Hypertens 12:388–397
Rajagopalan S, Kurz S, Munzel T, Tarpey M, Freeman BA, Griendling KK, Harrison DG (1996) Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotortone. J Clin Invest 97:1916–1923
Kalra D, Sivasubramanian N, Mann DL (2002) Angiotensin II induces tumor necrosis factor biosynthesis in the adult mammalian heart through a protein kinase C-dependent pathway. Circulation 105: 2198–2205
Feener EP, Northrup JM, Aiello LP, King GL (1995) Angiotensin II induces plasminogen activator inhibitor-1 and -2 expression in vascular endothelial and smooth muscle cells. J Clin Invest 95:1353–1362
Wright JW, Harding JW (2004) The brain angiotensin system and extracellular matrix molecules in neural plasticity, learning, and memory. Prog Neurobiol 72:263–293
Lips DJ, deWindt LJ, van Kraaij DJ, Doevendans PA (2003) Molecular determinants of myocardial hypertrophy and failure: alternative pathways for beneficial and maladaptive hypertrophy. Eur Heart J 24:883–896
Lombardi D, Gordon KL, Polinsky P, Suga S, Schwartz SM, Johnson RJ (1999) Salt-sensitive hypertension develops after short-term exposure to Angiotensin II. Hypertension 33:1013–1019
Ruiz-Ortega M, Lorenzo O, Ruperez M, Esteban V, Suzuki Y, Mezzano S et al (2001) Role of the renin-angiotensin system in vascular diseases: expanding the field. Hypertension 38:1382–1387
Yamada H, Fabris B, Allen AM, Jackson B, Johnston CI, Mendelsohn AO (1995) Localization of angiotensin converting enzyme in rat heart. Circ Res 68:141–149
Falkenhahn M, Franke F, Bohle RM, Zhu YC, Stauss HM, Bachmann S et al (1995) Cellular distribution of angiotensin-converting enzyme after myocardial infarction. Hypertension 25:219–226
Leri A, Claudio PP, Li Q (1998) Stretch-mediated release of angiotensin II induces myocyte apoptosis by activating p53 that enhances the local renin-angiotensin system and decreases the Bcl-2-to-Bax protein ratio in the cell. J Clin Invest 101:1326–1342
Ruzicka M, Skarda V, Leenen FH (1995) Effects of ACE inhibitors on circulating versus cardiac angiotensin II in volume overload-induced cardiac hypertrophy in rats. Circulation 92:3568–3573
Schunkert H, Ingelfinger JR, Hirsch AT (1992) Evidence for tissue-specific activation of renal angiotensinogen mRNA expression in chronic stable experimental heart failure. J Clin Invest 90:1523–1529
Lee YA, Liang CS, Lee MA, Lindpaintner K (1996) Local stress, not systemic factors, regulate gene expression of the cardiac renin-angiotensin system in vivo: a comprehensive study of all its components in the dog. Proc Natl Acad Sci USA 93:11035–11040
Schluter KD, Wollert KC (2004) Synchronization and integration of multiple hypertrophic pathways in the heart. Cardiovasc Res 63:367–372
Pagliaro P, Penna C (2005) Rethinking the renin-angiotensin system and its role in cardiovascular regulation. Cardiovasc Drugs & Therapy 19:77–87
Thomas WG, Brandenburger Y, Autelitano DJ, Pham T, Qian H, Hannan RD (2002) Adenoviral-directed expression of the type 1A angiotensin receptor promotes cardiomyocyte hypertrophy via transactivation of the epidermal growth factor receptor. Circ Res 90:135–142
Pellieux C, Foletti A, Peduto G, Aubert JF, Nussberger J, Beermann F et al (2001) Dilated cardiomyopathy and impaired cardiac hypertrophic response to angiotensin II in mice lacking FGF-2. J Clin Invest 108:1843–1851
Xia Y, Karmazyn M (2004) Obligatory role for endogenous endothelin in mediating the hypertrophic effects of phenylephrine and angiotensin II in neonatal rat ventricular myocytes: evidence for two distinct mechanisms for endothelin regulation. J Pharmacol Exp Ther 310:43–51
Kato H, Suzuki H, Tajima S, Ogata Y, Tominaga T, Sato A, Saruta T (1991) Angiotensin II stimulates collagen synthesis in cultured vascular smooth muscle cells. J Hypertens 9:17–22
Mifune M, Ohtsu H, Suzuki H, Nakashima H, Brailoiu E, Dun NJ et al (2005) Protein coupling and second messenger generation are indispensable for metalloprotease-dependent, heparin binding epidermal growth factor shedding through angiotensin II type-1 receptor. J Biol Chem 80:26592–26599
Fields RD, Itoh K (1996) Neural cell adhesion molecules in activity-dependent development and synaptic plasticity. Trends Neurosci 19:473–480
Schachner M (1997) Neural recognition molecules and synaptic plasticity. Curr Opin Cell Biol 9:627–634
Stamenkovic I (2003) Extracellular matrix remodeling: the role of matrix metalloproteinases. J Pathol 200:448–464
Jeng A, Gonnell N, Skiles J (2001) The design, structure, and therapeutic application of matrix metalloproteinase inhibitors. Curr Med Chem 8:425–474
Osler W (1992) The principle and practice of medicine. Appleton and Company, New York, pp 628–635
Gradman AH, Alfayoumi F (2006) From left ventricular hypertophy to congestive heart failure: management of hypertensive heart disease. Prog Cardiovasc Dis 48:326–341
Eichhorn EJ, Bristow MR (1996) Medical therapy can improve the biological properties of the chronically failing heart: a new era in the treatment of heart failure. Circulation 94:2285–2296
Wright JW, Harding JW (2006) Angiotensins in brain function. In: Lim R (ed) Handbook of neurochemistry and molecular neurobiology: neuroactive proteins and peptides. Springer Science, New York, pp 627–653
Stanton A (2003) Potential of renin inhibition in cardiovascular disease. J Renin Angiotensin Aldosterone Syst 4:6–10
Johnston CI (1990) Biochemistry and pharmacologyof the renin-angiotensin system. Drugs 39:21–31
Zisman ID, Abraham WT, Meiixell GE (1995) Angiotensin II formation in the intact human heart. Predominance of the angiotensin converting enzyme pathway. J Clin Invest 96:1490–1498
Dell’Italia IJ, Sabri A (2004) Activation of the renin-angiotensin system in hypertrophy and heart failure. In: Mann DL (ed) Heart Failure. Saunders, Philadelphia PA, pp 63–76
Liu YH, Yang XP, Sharov VG, Nass O, Sabbah HN, Peterson E, Carretero OA (1997) Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure: role of kinins and angiotensin II type 2 receptors. J Clin Invest 99:1926–1935
Brilla CG, Pick R, Tan LB, Janicki JS, Weber KT (1990) Remodeling of the rat right and left ventricles in experimental hypertension. Circ Res 67:1355–1364
Sabbah HN, Stein PD, Kono T, Gheorghiade M, Levine TB, Jafri S et al (1991) A canine model of chronic heart failure produced by multiple sequential coronary microembolizations. Am J Physiol 260:H1379–H1384
McKelvie RS, Yusuf S, Pericak D, Avezum A, Burns RJ, Probstfield J et al (1999) Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD pilot study investigators. Circulation 100:1056–1064
Pitt B, Reichek N, Willenbrock R, Zannad F, Phillips RA, Roniker B et al (2003) Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation 108:1831–1838
Hayashida W, Donckier J, Van Mechelen H, Charlier AA, Pouleur H (1997) Diastolic properties in canine hypertensive left ventricular hypertrophy: effects of angiotensin converting enzyme inhibition and angiotensin II type-1 receptor blockade. Cardiovasc Res 33:54–62
Wachtell K, Bella JN, Rokkedal J, Palmieri V, Papademetriou V, Dahlof B et al (2002) Change in diastolic left ventricular filing after one year of antihypertensive treatment: the losartan intervention for endpoint reduction in hypertension (LIFE) study. Circulation 105:1071–1076
Diez J, Querejeta R, Lopez B, Gonzalez A, Larman M, Ubago J (2002) Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation 105:2512–2517
Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ et al (2003) Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved trial. Lancet 362:777–781
Levy D, Anderson KM, Savage DD, Kannel WB, Christiansen JC, Castelli WP (1988) Echocardiographically detected left ventricular hypertrophy: prevalence and risk factors. The framingham heart study. Ann Intern Med 108:7–13
Bulpitt CJ, Cameron JD, Rajkumar C, Armstrong S, Connor M, Joshi J et al (1999) The effect of age on vascular compliance in man: which are the appropriate measures? J Hum Hypertens 13:753–758
Svanborg A (1997) Age-related changes in cardiac physiology. Can they be postponed or treated by drugs? Drugs Aging 10:463–472
Beckett NS, Connor M, Sadler JD, Fletcher AE, Bulpitt CJ (1999) Orthostatic fall in blood pressure in the very elderly hypertensive: results from the hypertension in the very elderly trial (HYVET)––pilot. J Hum Hypertens 13:839–840
Cleophas TJ, van Marum R (2003) Age-related decline in autonomic control of blood pressure: implications for the pharmacological management of hypertension in the elderly. Drugs Aging 20:313–319
Belmin J, Levy BI, Michel JB (1994) Changes in the renin-angiotensin-aldosterone axis in later life. Drugs Aging 5:391–400
Takeda R, Morimoto S, Uchida K, Miyamori I, Hashiba T (1980) Effect of age on plasma aldosterone response to exogenous angiotensin II in normotensive subjects. Acta Endocrinol 94:552–558
Dulin BR, Krum H (2006) Drug therapy of chronic heart failure in the elderly: the current state of clinical-trial evidence. Curr Opin Cardiol 21:393–399
Grady KL (2006) Management of heart failure in older adults. J Cardiovasc Nurs 21:S10–S14
Hunt SA, Abraham WT, Chin MH (2005) ACC/AHA 2005 Guideline update for the diagnosis and management of chronic heart failure in the adult. J Am Coll Cardiol. 46:1–82
Mangoni AA (2005) Cardiovascular drug therapy in elderly patients: specific age-related pharmacokinetic, pharmacodynamic and therapeutic considerations. Drugs Aging 22:913–941
Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, Redelmeier DA (2004) Rates of hyperkalemia after publication of the randomized aldactone evaluation study. N Engl J Med 351:543–551
Dunbar-Jacob J, Bohichick P, Mortimer MK, Sereika SM, Foley SM (2003) Medication adherence in persons with cardiovascular disease. J Cardiovasc Nurs 18:209–218
Stuart-Shor EM, Buselli EF, Carroll DL, Forman DE (2003) Are psychosocial factors associated with the pathogenesis and consequences of cardiovascular disease in the elderly? J Cardiovasc Nurs 18:169–183
Trenkwalder P (2002) Potential for antihypertensive treatment with an AT1-receptor blocker to reduce dementia in the elderly. J Hum Hypertens 16:S71–S75
Aronow WS (2006) Heart failure update: treatment of heart failure with a normal left ventricular ejection fraction in the elderly. Geriatrics 61:16–20
Aronow WS (2007) Treatment of heart failure with abnormal left ventricular systolic function in the elderly. Clin Geriatr Med 23:61–81
Kim S, Iwao H (2000) Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev 52:11–34
Schmieder RE, Martus P, Klingeil A (1996) Reversal of left ventricular hypertrophy in essential hypertension: a meta-analysis of randomized double-blind studies. JAMA 275:1507–1523
O’Connor CM, Arumugham P (2007) Inotropic drugs and neurohormonal antagonists in the treatment of HF in the elderly. Clin Geriatr Med 23:141–153
Thomas GN, Chan P, Tomlinson B (2006) The role of angiotensin II type 1 receptor antagonists in elderly patients with hypertension. Drugs Aging 23:131–155
Klingbeil AU, Schneider M, Martus P, Messerli FH, Schmieder RE (2003) A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 115:41–46
Sharpe M, Jarvis B, Goa KL (2001) Telmisartan: a review of its use in hypertension. Drugs 61:1501–1529
Simpson KL, McClellan KJ (2000) Losartan: a review of its use, with special focus on elderly patients. Drugs Aging 16:227–250
Warner GT, Jarvis B (2002) Olmesartan medoxomil. Drugs 62:1345–1353
Lip GY, Beevers DG (2003) More evidence on blocking the renin-angiotensin-aldosterone system in cardiovascular disease and the long-term treatment of hypertension: data from recent clinical trials (CHARM, EUROPA, ValHEFT, HOPE-TOO and SYST-EUR2). J Hum Hypertens 17:747–750
Unger T, Li J (2004) The role of the renin-angiotensin-aldosterone system in heart failure. J Renin Angiotensin Aldosterone Syst 5:S7–S10
Acknowledgments
The research from our laboratory presented in this review was supported by NIH grant RO1-HL64245-03, NSF grant IBN-0091337, and the Edward E. and Lucille I. Lainge Endowment for Alzheimer’s Research. We thank Mrs. Ruth Day for secretarial assistance provided during the course of writing this manuscript.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Wright, J.W., Mizutani, S. & Harding, J.W. Pathways involved in the transition from hypertension to hypertrophy to heart failure. Treatment strategies. Heart Fail Rev 13, 367–375 (2008). https://doi.org/10.1007/s10741-007-9060-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10741-007-9060-z